Skip to main content

Table 2 Mean malues ± SD of bone architecture parameters in the femoral metaphysis, determined by means of μCT scanning analyses in rats after 4 months of treatment

From: The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats

FEMORAL METAPHYSIS

SHAM (sham-operated controls)

(N = 10)

OVX (ovariectomized controls)

(N = 10)

WY OVX (ovariectomized, given Wyeth 14643)

(N = 9)

FENO OVX (ovariectomized, given fenofibrate)

(N = 10)

PIO OVX (ovariectomized, given pioglitazone)

(N = 9)

CORTICAL VOLUME

(Ct.V) (μm3)

28.77 ± 1.773

27.13 ± 1.551 a

28.14 ± 1.222

28.71 ± 1.795

23.37 ± 1.225 aaa, bbb, ccc, ddd

CORTICAL THICKNESS

(Ct.Th) (μm)

735.5 ± 22.90

694.4 ± 41.84 a

700.6 ± 21.83 aa

709.9 ± 28.52 a

594.7 ± 39.58 aaa, bb, cc, ddd

TRABECULAR BONE

VOLUME (BV) (μm3)

6.554 ± 0.8317

5.147 ± 0.5373 aa

5.697 ± 0.6074 a

5.615 ± 1.410

4.996 ± 1.048 aa

TOTAL

VOLUME (TV) (μm3)

21.85 ± 1.640

25.23 ± 1.734 a

23.65 ± 1.828

23.76 ± 2.448

28.58 ± 2.513 aaa, b, ccc, ddd

TRABECULAR

THICKNESS (Tb.Th) (μm)

148.3 ± 5.638

146.7 ± 6.034

144.1 ± 6.402 c

154.8 ± 11.59

141.5 ± 6.146 aa, cc

CONNECTIVITY

DENSITY (CD) (1/mm3)

14.20 ± 5.740

10.91 ± 2.118

17.91 ± 5.004 bb,c

12.01 ± 4.295

11.56 ± 2.533 dd

STRUCTURE MODEL

INDEX (SMI) (0.0-3.0)

0.6682 ± 0.2296

1.596 ± 0.2397 aaa

1.394 ± 0.1283 aaa, b

1.518 ± 0.2138 aaa

1.742 ± 0.2773 aaa, dd

TRABECULAR BONE

VOLUME FRACTION (BV/TV)

0.2991 ± 0.03208

0.2056 ± 0.02008 aaa

0.2389 ± 0.02892 aaa, b

0.2340 ± 0.04048 aaa

0.1744 ± 0.02128 aaa, bb, cc, ddd

  1. a, aa, aaa = p < 0.05, p < 0.01. p < 0.001 when compared to SHAM group
  2. b, bb, bbb = p < 0.05, p < 0.01, p < 0.001 when compared to OVX group
  3. c, cc, ccc = p < 0.05, p < 0.01, p < 0.001 when compared to FENO OVX group
  4. d, dd, ddd = p < 0.05, p < 0.01, p < 0.001 when compared to WY OVX group